Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) announced its earnings results on Thursday. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04), Morningstar.com reports. The company had revenue of $0.38 million for the quarter, compared to the consensus estimate of $0.07 million. Aurinia Pharmaceuticals had a negative return on equity of 30.34% and a negative net margin of 12,536.05%.
Shares of AUPH traded up $0.05 during mid-day trading on Friday, hitting $5.65. The company’s stock had a trading volume of 883,496 shares, compared to its average volume of 444,432. Aurinia Pharmaceuticals has a one year low of $4.41 and a one year high of $6.69. The stock has a market capitalization of $476.10 million, a price-to-earnings ratio of -6.14 and a beta of 2.22.
A number of equities research analysts have issued reports on AUPH shares. BidaskClub raised Aurinia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, July 14th. HC Wainwright reaffirmed a “buy” rating and set a $15.00 target price on shares of Aurinia Pharmaceuticals in a research report on Wednesday, September 26th. Cantor Fitzgerald set a $18.00 target price on Aurinia Pharmaceuticals and gave the stock a “buy” rating in a research report on Saturday, August 11th. ValuEngine raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, August 28th. Finally, Zacks Investment Research cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, October 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $11.79.
Aurinia Pharmaceuticals Company Profile
Aurinia Pharmaceuticals Inc, a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of autoimmune diseases in Canada, the United States, China, and Switzerland. The company is developing voclosporin, a calcineurin inhibitor for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis.
Featured Story: Google Finance Portfolio
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.